China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of 3SBio Inc. (HKG:1530), have entered into a licensing agreement for Sunshine Guojian’s 612 and 708 programs. Under the agreement, Shenyang 3SBio will obtain exclusive rights to develop, file regulatory applications, modify, use, manufacture, and market the products in mainland China.
Financial Terms
Shenyang 3SBio will pay Sunshine Guojian an upfront payment and milestone payments totaling RMB101.9 million (USD14 million), along with royalties of 15% of net sales.
Program Details
- 612: A HER2-targeted monoclonal antibody (mAb) at the pre-clinical stage, 612 has shown synergistic anti-tumor effects when combined with other anti-HER2 mAbs in pre-clinical in vivo pharmacological studies.
- 708: A bispecific antibody (BsAb) targeting PD-1 and TGF-β, 708 has demonstrated the ability to reactivate the anti-tumor activity of lymphocytes in preclinical pharmacology studies. The product has received clinical trial approval in China.-Fineline Info & Tech
